早期肝细胞癌肝切除后超出米兰标准复发的危险因素与长期预后:大规模多中心研究
该多中心队列纳入753例BCLC 0/A期肝细胞癌肝切除患者,中位随访51.8个月,18.3%发生超出米兰标准复发,复发后中位生存仅8.4个月(95%CI 7.0-9.8)。术前AFP>400 ng/mL、肿瘤>5.0 cm、多灶、微血管侵犯及未规律监测为独立危险因素,规律监测是可干预措施。
要点
- 早期肝癌肝切除后近1/5出现超出米兰标准复发,复发后中位生存不足1年。
- 术前AFP>400 ng/mL、肿瘤>5.0 cm、多灶、微血管侵犯增加超出米兰标准复发风险。
- 规律监测是可干预措施,有助于降低超出米兰标准复发并改善长期生存。
核心结论
- 早期肝细胞癌肝切除后约18.3%发生超出米兰标准复发,复发后中位生存仅8.4个月(95%CI 7.0-9.8)。
- 规律监测是降低超出米兰标准复发、改善长期生存的重要可干预措施。
研究设计与样本
- 多机构数据库回顾性队列,纳入753例因BCLC 0/A期肝细胞癌行肝切除的患者,中位随访51.8个月。
- 采用单因素和多因素Cox回归分析超出米兰标准复发的预测因素及复发后生存的危险因素。
主要发现
- 753例中138例(18.3%)发生超出米兰标准复发。
- 发生超出米兰标准复发的患者中,53例(38.4%)未进行规律监测(术后1年内间隔≤3个月、后续≤6个月)。
- 多因素分析显示术前AFP>400 ng/mL、肿瘤>5.0 cm、多灶病变、微血管侵犯及无/不规律复发监测与超出米兰标准复发风险独立相关。
- 超出米兰标准复发患者的中位复发后生存为8.4个月(95%CI 7.0-9.8)。
- 在超出米兰标准复发患者中,Child-Pugh B/C级、术后1年内早期复发、大血管侵犯/远处转移及复发非根治性治疗与更差复发后生存独立相关。
临床怎么用
- 对早期肝癌肝切除术后患者应落实规律监测:术后1年内间隔≤3个月、后续≤6个月。
- 对术前AFP>400 ng/mL、肿瘤>5.0 cm、多灶或微血管侵犯患者应加强复发监测与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on recurrence are important to inform surveillance and improve long-term surgical outcomes for patients with hepatocellular carcinoma. We sought to identify risk factors and long-term prognosis among patients who experienced beyond-Milan recurrence after hepatectomy for early-stage hepatocellular carcinoma. METHODS: Patients who underwent hepatectomy for Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma were identified from a multi-institutional database. Predictors of beyond-Milan recurrence and risk factors associated with post-recurrence survival among patients with beyond-Milan recurrence were assessed using univariate and multivariate Cox regression analyses. RESULTS: Among 753 patients (median follow-up, 51.8 months), 138 (18.3%) developed beyond-Milan recurrence. Regular surveillance (interval follow-up ≤3 months within 1 year and ≤6 months in subsequent years after surgery) was not carried out for 53 (38.4%) patients who developed beyond-Milan recurrence. On multivariate analysis, increased risk of beyond-Milan recurrence was independently associated with preoperative alpha-fetoprotein level >400 ng/mL, tumor size >5.0 cm, multifocal disease, microvascular invasion, and no/irregular recurrence surveillance. Median post-recurrence survival among patients with beyond-Milan recurrence was only 8.4 months (95% confidence interval: 7.0-9.8 months). Among patients who developed beyond-Milan recurrence, Child-Pugh grade B/C, early recurrence within 1 year after surgery, macrovascular invasion/distant metastasis, and noncurative treatment of recurrence were independent risk factors associated with worse post-recurrence survival. CONCLUSION: Nearly 1 in 5 patients developed beyond-Milan recurrence after hepatectomy for early-stage hepatocellular carcinoma. Patients with beyond-Milan recurrence had a median survival of less than 1 year after diagnosis of the recurrence. Regular surveillance is an important and actionable measure to decrease beyond-Milan recurrence and, in turn, improve long-term survival among patients treated with hepatectomy for hepatocellular carcinoma.
引用
- Feng ZH, Wang MD, Chen Z, et al. Risk factors and long-term prognosis of beyond-Milan recurrence after hepatectomy for BCLC stage 0/A hepatocellular carcinoma: A large-scale multicenter study. Surgery. 2022. PMID: 35868902. doi:10.1016/j.surg.2022.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。